Investing in a Start-Up

23 and me went public in june at a market value of three point five billion dollars. Is now closer to five billion dollars, and is expected to report about 56 million dollars in revenue in its latest quarter. The company is trying to expand from a category of modest consumer products into a field full of goliaths with research and development operations that dwarf anything it's fielding. If wagiski keeps achieving her goals, customers might one day pay 23 and me to assess their disease risk and pay for a treatment it later develops based on their d.